Next Article in Journal
Metabolic Interactions of Purine Derivatives with Human ABC Transporter ABCG2: Genetic Testing to Assess Gout Risk
Next Article in Special Issue
Longitudinal Assessment of Antimicrobial Susceptibility among Gram-Negative and Gram-Positive Organisms Collected from Italy as Part of the Tigecycline Evaluation and Surveillance Trial between 2004 and 2011
Previous Article in Journal
Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
Previous Article in Special Issue
What Goes around Comes around-A Comparative Study of the Influence of Chemical Modifications on the Antimicrobial Properties of Small Cyclic Peptides
Open AccessReview

A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011

1
IHMA Europe Sàrl, 9A Route de la Corniche, Epalinges 1066, Switzerland
2
International Health Management Associates, Inc; Schaumburg, IL 60173, IL, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2013, 6(11), 1335-1346; https://doi.org/10.3390/ph6111335
Received: 29 September 2013 / Revised: 26 October 2013 / Accepted: 28 October 2013 / Published: 1 November 2013
(This article belongs to the Special Issue Antimicrobial Agents)
Surveillance of antimicrobial agent resistance provides important information to guide microbiologists and infectious disease specialists understanding of the control and the spread of resistance mechanisms within the local environment. Continued monitoring of antimicrobial resistance patterns in the community and in local hospital environments is essential to guide effective empiric therapy. The Study for Monitoring Antimicrobial Resistance Trends (SMART) has monitored the in vitro susceptibility patterns of clinical Gram-negative bacilli to antimicrobial agents collected worldwide from intra-abdominal infections since 2002 and urinary tract infections since 2009. Resistance trends, with a particular focus on carbapenem resistance and the rate of extended-spectrum β-lactamases (ESBLs), were analyzed. Isolates from intra-abdominal infections (n = 92,086) and urinary-tract infections (n = 24,705) were collected and tested using Clinical and Laboratory Standards Institute methods. This review presents carbapenem susceptibility and ESBL rates over ten years of SMART study analysis, including key publications during this period. The SMART study has proved to be a valuable resource in determining pathogen prevalence and antibiotic susceptibility over the last ten years and continues to provide evidence for regulatory susceptibility breakpoints and clinical decision making. View Full-Text
Keywords: carbapenems; surveillance; Gram-negative; extended-spectrum β-lactamase carbapenems; surveillance; Gram-negative; extended-spectrum β-lactamase
Show Figures

Figure 1

MDPI and ACS Style

Morrissey, I.; Hackel, M.; Badal, R.; Bouchillon, S.; Hawser, S.; Biedenbach, D. A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals 2013, 6, 1335-1346.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop